Newsletters
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
Manufacturing underpins access in LMICs: An update on cefiderocol
Dear All, No one is safe until we’re all safe! In the 7 April 2025 newsletter on antibiotic access (“UNSLAP: You
Read More >
Most current global summary of Pull incentives
Dear All, I was recently asked about a ready summary of the current state of play of Pull incentives around
Read More >
Sign-on letter encouraging AMR funding in the FY2026 US budget
Dear All, If you represent a US-based organization with an interest in AMR, there is an opportunity to sign a
Read More >
UNSLAP: You reach for the antibiotic … and it’s not there!
Dear All (with thanks to Louise for co-authoring and with a wonkish alert … settle in for the ride!), Today’s
Read More >
Antibacterial R&D is very hard! Two great pipeline reviews + an Industry-level view
Dear All (and with thanks to Stephan Harbarth for co-authoring this newsletter), A new review by Ursula Theuretzbacher and colleagues
Read More >
WHO pipeline reviews: Antifungal agents and fungal diagnostics
Dear All, As you know, WHO have been steadfastly producing both priority pathogens lists (PPLs) and pipeline reviews. My current
Read More >
Now live: HERA’s call for rapid point-of-care susceptibility devices
Dear All, I wrote in the 19 Feb 2025 newsletter about HERA’s 13m EUR call for rapid point-of-care susceptibility devices. The
Read More >
Updates: CARB-X TPPs; Independent Panel for Evidence for Action against AMR
Dear All, Two quick updates this evening. First, you will recall that CARB-X have announced their initial 2025 funding round
Read More >
Unexpected resistance: The tale of rifaximin and daptomycin
Dear All (and with thanks to Patricia Bradford for taking the lead on this newsletter): Today, this paper in Nature
Read More >
CARB-X announces its 2025 funding round
Dear All, At BEAM’s AMR Conference in Basel, Team CARB-X have today announced their 2025 funding round. Key points: Two
Read More >
Ineos Oxford Institute for AMR seeks Director
Dear All, I have learned that the Ineos Oxford Institute for Antimicrobial Research (IOI) has started a job search for
Read More >
HERA: 13m EUR call for rapid point-of-care susceptibility devices
24 Mar 2025 update: The call is live! It’s entitled “Development of a Rapid Point-of-care Antimicrobial Susceptibility Testing Diagnostic Medical
Read More >
EMA: 16m EUR to fund regulatory science research
Dear All, EMA have recently posted a call for tenders under which they seek to “procure the services of research
Read More >
Sign-on Letter to Preserve Upcoming ACIP Meeting
Dear All, The Advisory Committee on Immunization Practices (ACIP) is scheduled to meet 26-28 Feb 2025 (see links below my signature
Read More >
ESCMID 2025: Science Policy Forum and Pipeline Day events
Dear All, If you are attending ESCMID Global in Vienna this year, mark your calendar for two major events. I
Read More >
Gates/Novo Nordisk/Wellcome Grand Challenge: Gr-ADI, the Gram-Negative Antibiotic Discovery Innovator
Dear All, A huge announcement today backed by the combined power of the Gates Foundation, Novo Nordisk, and Wellcome! I
Read More >
Jan 2025 PACCARB meeting cancelled as new administration takes the reins
Dear All, Sadly, I must report that the 27th meeting of PACCARB (the US Presidential Advisory Council on Combatting Antibiotic-Resistant
Read More >
NOHF-Zoonoses, NARMS, and more: US action on One Health, Surveillance, and much more
Dear All, Three things for today along with some great acronyms! To start, we have an announcement of the first
Read More >
Italy delivers a national pull incentive (with a budget of EUR 100 million a year)!
Dear All (and with thanks to Damiano for taking the lead on this newsletter), We start the new year with good
Read More >
WHO-GARDP: Policy interventions for (mostly acute) antibiotic shortages
Dear All, I wrote in the 1 Dec 2024 newsletter about the excellent paper by Baraldi et al. that introduced
Read More >